Vaccines (Dec 2020)

Comparison of Four SARS-CoV-2 Neutralization Assays

  • Lydia Riepler,
  • Annika Rössler,
  • Albert Falch,
  • André Volland,
  • Wegene Borena,
  • Dorothee von Laer,
  • Janine Kimpel

DOI
https://doi.org/10.3390/vaccines9010013
Journal volume & issue
Vol. 9, no. 1
p. 13

Abstract

Read online

Neutralizing antibodies are a major correlate of protection for many viruses including the novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce neutralizing antibodies to render effective protection from infection. A variety of in vitro assays for the detection of SARS-CoV-2 neutralizing antibodies has been described. However, validation of the different assays against each other is important to allow comparison of different studies. Here, we compared four different SARS-CoV-2 neutralization assays using the same set of patient samples. Two assays used replication competent SARS-CoV-2, a focus forming assay and a TCID50-based assay, while the other two assays used replication defective lentiviral or vesicular stomatitis virus (VSV)-based particles pseudotyped with SARS-CoV-2 spike. All assays were robust and produced highly reproducible neutralization titers. Titers of neutralizing antibodies correlated well between the different assays and with the titers of SARS-CoV-2 S-protein binding antibodies detected in an ELISA. Our study showed that commonly used SARS-CoV-2 neutralization assays are robust and that results obtained with different assays are comparable.

Keywords